Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans


#138737

49pages

GBI Research

$ 3500

In Stock


Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

GBI Research, the leading business intelligence provider has released its latest research report, Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans. The report focuses on the key insights into the biodefense industry. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the biodefense industry. The report examines the bioterrorist events which have resulted in Research and Development (R&D) in the industry. The pharmaceutical countermeasures and treatments by Europe and the US. The report analysis the work of the industry in terms of past, present and future pharmaceutical research, development and production to counter or treat diseases caused by biological attack.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in house analysis by GBI Researchs team of industry experts.

GBI Research also analyzed pipeline of category A pathogens namely, anthrax, small pox, viral hemorrhagic fever, plague and tularemia. Anthrax (24%), smallpox (32%) and viral hemorrhagic fever (39%) contributed a total of 95% of the molecules to the biodefense industry pipeline. Viral hemorrhagic fever, anthrax and small pox are among the most researched diseases in the biodefense industry. It is attributable because of scale of destruction that these two pathogens can cause. According to GBI Research analysis, Emergent BioSolutions and SIGA Technologies were awarded a total of 15 contracts between 2007 and 2012.

Scope

  • Data and analysis on the biodefense industry.
  • The competitive landscape of the biodefense industry.
  • Key Biodefense Contracts that took place from biodefense industry.

Reasons to buy

  • The major trends in R&D in the biodefense industry
  • Develop market-entry and market expansion strategies by identifying the potential region and segments poised for strong growth.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8

2 Biodefense Industry Introduction 9

3 Biodefense Industry Regulatory Environment 10
3.1 Regulatory Agencies 10
3.1.1 Food and Drug Administration 10
3.1.2 Project Bioshield 10

4 Biodefense Industry Pathogens and Pipeline 12
4.1 Anthrax 12
4.1.1 Introduction 12
4.1.2 Treatment Options 12
4.1.3 Anthrax Product Pipeline Analysis 13
4.2 Smallpox 14
4.2.1 Introduction 14
4.2.2 Treatment Options 14
4.2.3 Smallpox Product Pipeline Analysis 15
4.3 Viral Hemorrhagic Fevers 16
4.3.1 Introduction 16
4.3.2 Treatment Options 17
4.3.3 Viral Hemorrhagic Fevers Product Pipeline Analysis 17
4.4 Plague 19
4.4.1 Introduction 19
4.4.2 Treatment Options 19
4.4.3 Plague Product Pipeline Analysis 19
4.5 Tularemia 20
4.5.1 Introduction 20
4.5.2 Treatment Options 20
4.5.3 Tularemia Product Pipeline Analysis 20

5 Biodefense Industry Funding 21
5.1 Introduction 21
5.2 Biodefense Funding The US 21
5.2.1 Department of Health and Human Services 21
5.2.2 Biomedical Research and Development Authority 21
5.2.3 NIH Challenge Grants in Health and Science Research 22
5.2.4 NIH Cooperative Research and Development Agreement (CRADA) 22
5.2.5 NIH Small Business Biodefense Program Awards 22
5.2.6 Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases 23
5.2.7 Defense Threat Reduction Agency (DTRA) 26
5.2.8 US Army Medical Research Institute of Infectious Diseases (USAMRIID) 27
5.2.9 Defense Advanced Research Projects Agency (DARPA) 27
5.3 Biodefense Funding Europe 27
5.3.1 EU Biodefense Programs 27
5.3.2 European Defense Agency (EDA) 27
5.3.3 Bio-Edep 27
5.3.4 New and Emerging Science and Technology (NEST) 28
5.3.5 Health Protection Agency (HPA) 28

6 Biodefense Industry Case Study 29
6.1 Case Study Anthrax Contamination 29
6.1.1 Company Sabre Technical Services LLC 29
6.1.2 Solution Facility Decontamination with Chlorine Dioxide (ClO2) Gas 29

7 Biodefense Industry Competitive Landscape 31
7.1 Achaogen 31
7.1.1 Biodefense Contracts 31
7.2 Alnylam Pharmaceuticals 31
7.2.1 Biodefense Contracts 31
7.3 Bavarian Nordic 32
7.3.1 Biodefense Contracts 32
7.4 Cleveland BioLabs 33
7.4.1 Biodefense Contracts 33
7.5 Dynavax Technologies Inc. 34
7.5.1 Biodefense Contracts 34
7.6 Dynport Vaccine Company LLC (DVC) 34
7.6.1 Biodefense Contracts 34
7.7 Elusys Therapeutics 35
7.7.1 Biodefense Contracts 35
7.8 Emergent BioSolutions 36
7.8.1 Biodefense Contracts 37
7.9 Ichor Medical Systems 39
7.9.1 Biodefense Contracts 39
7.10 Nanotherapeutics 39
7.10.1 Biodefense Contracts 39
7.11 PharmAthene 40
7.11.1 Biodefense Contracts 40
7.12 SIGA Technologies 41
7.12.1 Biodefense Contracts 41
7.13 XOMA 43
7.13.1 Biodefense Contracts 43

8 Biodefense Industry Appendix 44
8.1 Market Definitions 44
8.2 Abbreviations 44
8.3 Bibliography 46
8.4 Research Methodology 47
8.4.1 Coverage 47
8.4.2 Secondary Research 48
8.4.3 Primary Research 48
8.4.4 Section-Wise Methodology 48
8.4.5 Expert Panel Validation 49
8.5 Contact Us 49
8.6 Disclaimer 49

Table 1: Biodefense Industry, Anthrax Pipeline Analysis, Discovery Molecules, 2012 13
Table 2: Biodefense Industry, Anthrax Pipeline Analysis, Pre-Clinical Molecules, 2012 13
Table 3: Biodefense Industry, Anthrax Pipeline Analysis, Phase I Molecules, 2012 13
Table 4: Biodefense Industry, Anthrax Pipeline Analysis, Phase II Molecules, 2012 13
Table 5: Biodefense Industry, Anthrax Pipeline Analysis, Phase III Molecules, 2012 14
Table 6: Biodefense Industry, Anthrax Pipeline Analysis, NDA Filed Molecules, 2012 14
Table 7: Biodefense Industry, Smallpox Pipeline Analysis, Discovery Molecules, 2012 15
Table 8: Biodefense Industry, Smallpox Pipeline Analysis, Pre-Clinical Molecules, 2012 15
Table 9: Biodefense Industry, Smallpox Pipeline Analysis, Phase I Molecules, 2012 15
Table 10: Biodefense Industry, Smallpox Pipeline Analysis, Phase II Molecules, 2012 16
Table 11: Biodefense Industry, Smallpox Pipeline Analysis, Phase III Molecules, 2012 16
Table 12: Biodefense Industry, Smallpox Pipeline Analysis, NDA Filed Molecules, 2012 16
Table 13: Biodefense Industry, Viral Hemorrhagic Fever Pipeline Analysis, Phase I Molecules, 2012 17
Table 14: Biodefense Industry, Viral Hemorrhagic Fever Pipeline Analysis, Phase II Molecules, 2012 18
Table 15: Biodefense Industry, Viral Hemorrhagic Fever Pipeline Analysis, Phase III Molecules, 2012 18
Table 16: Biodefense Industry, Plague Pipeline Analysis, Phase I Molecules, 2012 19
Table 17: Biodefense Industry, Plague Pipeline Analysis, Phase II Molecules, 2012 19
Table 18: Biodefense Industry, Tularemia Pipeline Analysis, Phase II Molecules, 2012 20